APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD19-targeted CAR-T Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CD19-targeted CAR-T Cell Therapy Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry ResearchCD19-targeted CAR-T Cell Therapy Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal CD19-targeted CAR-T Cell Therapy Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal CD19-targeted CAR-T Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD19-targeted CAR-T Cell Therapy Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal CD19-targeted CAR-T Cell Therapy Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global CD19-targeted CAR-T Cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CD19-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CD19-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CD19-targeted CAR-T Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CD19-targeted CAR-T Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CD19-targeted CAR-T Cell Therapy market include Bristol-Myers Squibb (Breyanzi), Gilead (Yescarta&Tecartus), Novartis (Kymriah), FOSUNKite (Yescarta), Juventas and Shanghai Yaoming Juno (Carteyva), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CD19-targeted CAR-T Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CD19-targeted CAR-T Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CD19-targeted CAR-T Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CD19-targeted CAR-T Cell Therapy market.

CD19-targeted CAR-T Cell Therapy Segment by Company

Bristol-Myers Squibb (Breyanzi)

Gilead (Yescarta&Tecartus)

Novartis (Kymriah)

FOSUNKite (Yescarta)

Juventas

Shanghai Yaoming Juno (Carteyva)

CD19-targeted CAR-T Cell Therapy Segment by Type

Yescarta

Tecartus

Kymriah

Others

CD19-targeted CAR-T Cell Therapy Segment by Application

Lymphoma

Lymphocytic Leukemia

CD19-targeted CAR-T Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global CD19-targeted CAR-T Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CD19-targeted CAR-T Cell Therapy key companies, revenue, market share, and recent developments.

3. To split the CD19-targeted CAR-T Cell Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CD19-targeted CAR-T Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CD19-targeted CAR-T Cell Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze CD19-targeted CAR-T Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD19-targeted CAR-T Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD19-targeted CAR-T Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD19-targeted CAR-T Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CD19-targeted CAR-T Cell Therapy industry.

Chapter 3: Detailed analysis of CD19-targeted CAR-T Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CD19-targeted CAR-T Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CD19-targeted CAR-T Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CD19-targeted CAR-T Cell Therapy Industry Trends Table 2. CD19-targeted CAR-T Cell Therapy Industry Drivers Table 3. CD19-targeted CAR-T Cell Therapy Industry Opportunities and Challenges Table 4. CD19-targeted CAR-T Cell Therapy Industry Restraints Table 5. Global CD19-targeted CAR-T Cell Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CD19-targeted CAR-T Cell Therapy Revenue Share by Company (2021-2026) Table 7. Global CD19-targeted CAR-T Cell Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CD19-targeted CAR-T Cell Therapy Key Company Manufacturing Base & Headquarters Table 9. Global CD19-targeted CAR-T Cell Therapy Company, Product Type & Application Table 10. Global CD19-targeted CAR-T Cell Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CD19-targeted CAR-T Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Yescarta Table 15. Significant Companies of Tecartus Table 16. Significant Companies of Kymriah Table 17. Significant Companies of Others Table 18. Global CD19-targeted CAR-T Cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global CD19-targeted CAR-T Cell Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global CD19-targeted CAR-T Cell Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Type (2021-2026) Table 22. Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Lymphoma Table 24. Significant Companies of Lymphocytic Leukemia Table 25. Global CD19-targeted CAR-T Cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global CD19-targeted CAR-T Cell Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global CD19-targeted CAR-T Cell Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Application (2021-2026) Table 29. Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Application (2027-2032) Table 30. Global CD19-targeted CAR-T Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global CD19-targeted CAR-T Cell Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Region (2021-2026) Table 33. Global CD19-targeted CAR-T Cell Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Region (2027-2032) Table 35. Global CD19-targeted CAR-T Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global CD19-targeted CAR-T Cell Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global CD19-targeted CAR-T Cell Therapy Sales Value Market Share by Country (2021-2026) Table 38. Global CD19-targeted CAR-T Cell Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global CD19-targeted CAR-T Cell Therapy Sales Value Market Share by Country (2027-2032) Table 40. Bristol-Myers Squibb (Breyanzi) Company Information Table 41. Bristol-Myers Squibb (Breyanzi) Business Overview Table 42. Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 44. Bristol-Myers Squibb (Breyanzi) Recent Development Table 45. Gilead (Yescarta&Tecartus) Company Information Table 46. Gilead (Yescarta&Tecartus) Business Overview Table 47. Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 49. Gilead (Yescarta&Tecartus) Recent Development Table 50. Novartis (Kymriah) Company Information Table 51. Novartis (Kymriah) Business Overview Table 52. Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 54. Novartis (Kymriah) Recent Development Table 55. FOSUNKite (Yescarta) Company Information Table 56. FOSUNKite (Yescarta) Business Overview Table 57. FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 59. FOSUNKite (Yescarta) Recent Development Table 60. Juventas Company Information Table 61. Juventas Business Overview Table 62. Juventas CD19-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Juventas CD19-targeted CAR-T Cell Therapy Product Portfolio Table 64. Juventas Recent Development Table 65. Shanghai Yaoming Juno (Carteyva) Company Information Table 66. Shanghai Yaoming Juno (Carteyva) Business Overview Table 67. Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Product Portfolio Table 69. Shanghai Yaoming Juno (Carteyva) Recent Development Table 70. Research Programs/Design for This Report Table 71. Authors List of This Report Table 72. Secondary Sources Table 73. Primary Sources List of Figures Figure 1. CD19-targeted CAR-T Cell Therapy Product Image Figure 2. Global CD19-targeted CAR-T Cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD19-targeted CAR-T Cell Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global CD19-targeted CAR-T Cell Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Yescarta Image Figure 8. Tecartus Image Figure 9. Kymriah Image Figure 10. Others Image Figure 11. Global CD19-targeted CAR-T Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global CD19-targeted CAR-T Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Type (2021-2032) Figure 14. Lymphoma Image Figure 15. Lymphocytic Leukemia Image Figure 16. Global CD19-targeted CAR-T Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global CD19-targeted CAR-T Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Application (2021-2032) Figure 19. Global CD19-targeted CAR-T Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. North America CD19-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Europe CD19-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific CD19-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. South America CD19-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa CD19-targeted CAR-T Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Yescarta
  • Tecartus
  • Kymriah
  • Others
Applications
  • Lymphoma
  • Lymphocytic Leukemia
Companies covered
  • Bristol-Myers Squibb (Breyanzi)
  • Gilead (Yescarta&Tecartus)
  • Novartis (Kymriah)
  • FOSUNKite (Yescarta)
  • Juventas
  • Shanghai Yaoming Juno (Carteyva)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CD19-targeted CAR-T Cell Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CD19-targeted CAR-T Cell Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CD19-targeted CAR-T Cell Therapy Market Dynamics
  1. 2.1 CD19-targeted CAR-T Cell Therapy Industry Trends
  2. 2.2 CD19-targeted CAR-T Cell Therapy Industry Drivers
  3. 2.3 CD19-targeted CAR-T Cell Therapy Industry Opportunities and Challenges
  4. 2.4 CD19-targeted CAR-T Cell Therapy Industry Restraints
3 CD19-targeted CAR-T Cell Therapy Market by Company
  1. 3.1 Global CD19-targeted CAR-T Cell Therapy Company Revenue Ranking in 2025
  2. 3.2 Global CD19-targeted CAR-T Cell Therapy Revenue by Company (2021-2026)
  3. 3.3 Global CD19-targeted CAR-T Cell Therapy Company Ranking (2024-2026)
  4. 3.4 Global CD19-targeted CAR-T Cell Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global CD19-targeted CAR-T Cell Therapy Company Product Type and Application
  6. 3.6 Global CD19-targeted CAR-T Cell Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CD19-targeted CAR-T Cell Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CD19-targeted CAR-T Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CD19-targeted CAR-T Cell Therapy Market by Type
  1. 4.1 CD19-targeted CAR-T Cell Therapy Type Introduction
  2. 4.1.1 Yescarta
  3. 4.1.2 Tecartus
  4. 4.1.3 Kymriah
  5. 4.1.4 Others
  6. 4.2 Global CD19-targeted CAR-T Cell Therapy Sales Value by Type
  7. 4.2.1 Global CD19-targeted CAR-T Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global CD19-targeted CAR-T Cell Therapy Sales Value by Type (2021-2032)
  9. 4.2.3 Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Type (2021-2032)
5 CD19-targeted CAR-T Cell Therapy Market by Application
  1. 5.1 CD19-targeted CAR-T Cell Therapy Application Introduction
  2. 5.1.1 Lymphoma
  3. 5.1.2 Lymphocytic Leukemia
  4. 5.2 Global CD19-targeted CAR-T Cell Therapy Sales Value by Application
  5. 5.2.1 Global CD19-targeted CAR-T Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global CD19-targeted CAR-T Cell Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global CD19-targeted CAR-T Cell Therapy Sales Value Share by Application (2021-2032)
6 CD19-targeted CAR-T Cell Therapy Regional Value Analysis
  1. 6.1 Global CD19-targeted CAR-T Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CD19-targeted CAR-T Cell Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global CD19-targeted CAR-T Cell Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global CD19-targeted CAR-T Cell Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  7. 6.3.2 North America CD19-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe CD19-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CD19-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  16. 6.6.2 South America CD19-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CD19-targeted CAR-T Cell Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CD19-targeted CAR-T Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 CD19-targeted CAR-T Cell Therapy Country-level Value Analysis
  1. 7.1 Global CD19-targeted CAR-T Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CD19-targeted CAR-T Cell Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global CD19-targeted CAR-T Cell Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global CD19-targeted CAR-T Cell Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CD19-targeted CAR-T Cell Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CD19-targeted CAR-T Cell Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CD19-targeted CAR-T Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb (Breyanzi)
  2. 8.1.1 Bristol-Myers Squibb (Breyanzi) Company Information
  3. 8.1.2 Bristol-Myers Squibb (Breyanzi) Business Overview
  4. 8.1.3 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb (Breyanzi) CD19-targeted CAR-T Cell Therapy Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb (Breyanzi) Recent Developments
  7. 8.2 Gilead (Yescarta&Tecartus)
  8. 8.2.1 Gilead (Yescarta&Tecartus) Company Information
  9. 8.2.2 Gilead (Yescarta&Tecartus) Business Overview
  10. 8.2.3 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gilead (Yescarta&Tecartus) CD19-targeted CAR-T Cell Therapy Product Portfolio
  12. 8.2.5 Gilead (Yescarta&Tecartus) Recent Developments
  13. 8.3 Novartis (Kymriah)
  14. 8.3.1 Novartis (Kymriah) Company Information
  15. 8.3.2 Novartis (Kymriah) Business Overview
  16. 8.3.3 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis (Kymriah) CD19-targeted CAR-T Cell Therapy Product Portfolio
  18. 8.3.5 Novartis (Kymriah) Recent Developments
  19. 8.4 FOSUNKite (Yescarta)
  20. 8.4.1 FOSUNKite (Yescarta) Company Information
  21. 8.4.2 FOSUNKite (Yescarta) Business Overview
  22. 8.4.3 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 FOSUNKite (Yescarta) CD19-targeted CAR-T Cell Therapy Product Portfolio
  24. 8.4.5 FOSUNKite (Yescarta) Recent Developments
  25. 8.5 Juventas
  26. 8.5.1 Juventas Company Information
  27. 8.5.2 Juventas Business Overview
  28. 8.5.3 Juventas CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Juventas CD19-targeted CAR-T Cell Therapy Product Portfolio
  30. 8.5.5 Juventas Recent Developments
  31. 8.6 Shanghai Yaoming Juno (Carteyva)
  32. 8.6.1 Shanghai Yaoming Juno (Carteyva) Company Information
  33. 8.6.2 Shanghai Yaoming Juno (Carteyva) Business Overview
  34. 8.6.3 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Yaoming Juno (Carteyva) CD19-targeted CAR-T Cell Therapy Product Portfolio
  36. 8.6.5 Shanghai Yaoming Juno (Carteyva) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst